Last reviewed · How we verify
Esketamine combined with dexmedetomidine
Esketamine combined with dexmedetomidine is a Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently FDA-approved. Also known as: E+D, S-ketamine combined with dexmedetomidine.
At a glance
| Generic name | Esketamine combined with dexmedetomidine |
|---|---|
| Also known as | E+D, S-ketamine combined with dexmedetomidine |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium (PHASE4)
- Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality (NA)
- Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality in ICU Patients (PHASE4)
- Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia (PHASE4)
- Sedation With Dexmedetomidine-esketamine Combination and Delirium in ICU Patients (PHASE4)
- Dexmedetomidine-esketamine-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia (PHASE4)
- The Effect of Esketamine Combined With Dexmedetomidine on Postoperative Recovery Quality in Patients Undergoing Thoracoscopic Surgery (NA)
- Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Esketamine combined with dexmedetomidine CI brief — competitive landscape report
- Esketamine combined with dexmedetomidine updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI
Frequently asked questions about Esketamine combined with dexmedetomidine
What is Esketamine combined with dexmedetomidine?
Esketamine combined with dexmedetomidine is a Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University.
Who makes Esketamine combined with dexmedetomidine?
Esketamine combined with dexmedetomidine is developed and marketed by The First Affiliated Hospital with Nanjing Medical University (see full The First Affiliated Hospital with Nanjing Medical University pipeline at /company/the-first-affiliated-hospital-with-nanjing-medical-university).
Is Esketamine combined with dexmedetomidine also known as anything else?
Esketamine combined with dexmedetomidine is also known as E+D, S-ketamine combined with dexmedetomidine.
What development phase is Esketamine combined with dexmedetomidine in?
Esketamine combined with dexmedetomidine is FDA-approved (marketed).
Related
- Manufacturer: The First Affiliated Hospital with Nanjing Medical University — full pipeline
- Also known as: E+D, S-ketamine combined with dexmedetomidine
- Compare: Esketamine combined with dexmedetomidine vs similar drugs
- Pricing: Esketamine combined with dexmedetomidine cost, discount & access